ArticleBMC gastroenterology2025
Efficacy and safety of ultraviolet C therapy for the eradication of Helicobacter pylori.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHelicobacter pylori (Hp) is a globally prevalent gastrointestinal pathogen and a major etiological agent in various digestive tract disorders. Ultra violet C (UVC) light represents a promising physical modality for the treatment of Hp infection, owing to its capacity for non-invasive endoscopic delivery to eradicate the bacterium within the gastric environment.
objectiveThe purpose of this study was to investigate the efficacy and safety of UVC-LED (254/265/275 nm) in the treatment of Hp, both in vitro and in vivo.
methodsThe bactericidal effect of UVC-LED irradiation against H. pylori was assessed in vitro and in an animal infection model. Gastric tissue damage and therapeutic efficacy were evaluated via H&E, γ-H2AX, TUNEL staining and digestive function of the stomach.
resultsUVC-LEDs emitting at 254, 265, and 275 nm exhibited significant anti-H. pylori activity. However, a clear divergence in safety profiles was observed. The 275 nm wavelength achieved substantial bacterial load reduction while inducing minimal DNA damage and cellular apoptosis, as evidenced by significantly lower levels of γ-H2AX and TUNEL positivity compared to the 254 nm and 265 nm group at the critical 1-day and 3-day timepoints (p < 0.05). Histological analysis confirmed that this attenuated cellular damage correlated with preserved mucosal architecture in the 275 nm treatment group. Furthermore, none of the three wavelengths showed any significant adverse impact on gastric digestive function.
conclusionsThe 275 nm UVC-LED emerges as an effective and tissue-compatible physical therapy for H. pylori infection, combining robust bactericidal activity with enhanced mucosal safety. This modality shows promise as a novel complementary approach to conventional antibiotic-based regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.